Trial Outcomes & Findings for Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment (NCT NCT00210249)

Results Overview

Number of participant deaths observed during the course of the study

Recruitment status

COMPLETED

Target enrollment

364 participants

Primary outcome timeframe

6 months after inclusion

Results posted on

2022-02-04

Participant Flow

Participant milestones

Participant milestones
Measure	Eligible Patients Patients satisfying eligibility criteria
Overall Study STARTED	364
Overall Study COMPLETED	348
Overall Study NOT COMPLETED	16

Reasons for withdrawal

Reasons for withdrawal
Measure	Eligible Patients Patients satisfying eligibility criteria
Overall Study Lost to Follow-up	5
Overall Study Protocol Violation	11

Baseline Characteristics

Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Eligible Patients n=364 Participants Patients satisfying eligibility criteria
Age, Continuous	77.45 years n=5 Participants
Sex: Female, Male Female	157 Participants n=5 Participants
Sex: Female, Male Male	207 Participants n=5 Participants
Region of Enrollment France	364 participants n=5 Participants

PRIMARY outcome

Timeframe: 6 months after inclusion

Population: Eleven patients did not complete the geriatric evaluation, and an additional five patients were lost to follow-up before 6 months, which left 348 analyzed patients

Number of participant deaths observed during the course of the study

Outcome measures

Outcome measures
Measure	Eligible Patients n=348 Participants Patients satisfying eligibility criteria
Number of Participant Deaths	56 Participants

Adverse Events

Eligible Patients

Serious events: 0 serious events

Other events: 0 other events

Deaths: 56 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Pr Simone Mathoulin-Pélissier

Institut Bergonié, Comprehensive Cancer Center, Bordeaux, FR

Phone: +33 (0)5 56 33 33 33

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place